NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Health Information Services · USD

Omnicell, Inc. (OMCL) Stock Analysis

Omnicell, Inc. (OMCL) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

OMCL

$34.37

−$0.45 (−1.29%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OMCL with… →

OMCL Key Statistics

As of Sep 4, 2026
Trading
Open
$34.36
Previous Close
$34.82
Day's Range
34.00–34.70
52-Week Range
29.06–55.00
Volume
873.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.97
Valuation
Market Cap
$1.56B
P/E Ratio
40.92
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
16.44
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
15.40
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.25
EPS (ttm)Profit attributable to each share over the last twelve months.
0.84
Financials (FY)
Revenue (FY)
$1.18B+6.53%
Net Income (FY)
$2.05M−83.62%
Profit marginThe share of revenue left as profit after all costs and taxes.
3.14%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.48M
1-Year Return
+3.77%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
774.15K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OMCL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.13%
2025+1.75%
2024+18.31%
2023−25.37%
2022−72.06%
2021+50.34%
2020+46.87%
2019+33.44%
2018+26.27%
2017+43.07%
2016 (partial year)−10.95%

As of September 4, 2026.

OMCL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.18B$2.05M0.2%
2024$1.11B$12.53M1.1%
2023$1.15B−$20.37M−1.8%
2022$1.30B$5.65M0.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.18B$503.44M$5.16M$2.05M0.2%
2024$1.11B$471.00M$337.00K$12.53M1.1%
2023$1.15B$496.84M−$34.87M−$20.37M−1.8%
2022$1.30B$588.99M−$2.32M$5.65M0.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OMCL Valuation vs Health Information Services Median

Median of 53 stocks
MetricOMCLHealth Information Services medianvs median
P/E40.9241.131% below
P/S ratio1.252.6653% below
Profit margin3.14%0.00%3.1 pts above

Medians across 53 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Omnicell, Inc. (OMCL) carries a market capitalisation of $1.56B. It is classified in the Health Information Services industry, within the Healthcare sector. Headcount on file is 3,485.

The most recent close on file for OMCL is $34.37, dated September 4, 2026. That is −$0.45 (−1.29%) against the previous close. The 52-week range on file runs from $29.06 to $55.00. The latest close sits 18.27% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.18B. That is +6.53% against the prior fiscal year, when revenue was $1.11B. The same year closed with net income of $2.05M. That is −83.62% against the prior fiscal year. Profit margin runs at 3.14%. That is 3.1 percentage points above the Health Information Services median of 0%. Trailing earnings per share are 0.84.

Across the 4 fiscal years on file, revenue moves from $1.30B in 2022 to $1.18B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 40.92. That is 0.51% below the Health Information Services median of 41.13. The forward P/E on file is 16.44. The PEG ratio, which sets the P/E against expected earnings growth, reads 15.4. The price-to-sales ratio is 1.25. On price-to-sales that is 52.84% below the Health Information Services median of 2.66. 53 Health Information Services companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +3.77%. Across 10 years the annualized return works out at −1.23%. Beta against the wider market is reported at 0.97. Daily returns over the trailing 10 years annualize to a volatility of 44.34%.

Growth & Income

No dividend is on file for OMCL.

2026 is still running; the price is −24.13% year to date. The strongest complete calendar year on file is 2021 at +50.34%; the weakest is 2022 at −72.06%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Omnicell, Inc. (OMCL) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Omnicell, Inc. OMCL $1.56B 40.9
Veeva Systems Inc. VEEV $44.54B 45.0
BrightSpring Health Services, Inc. BTSG $12.02B 54.7
Tempus AI, Inc. TEM $11.66B —

The Health Information Services industry average P/E ratio is 41.1x. Omnicell, Inc. trades at a P/E of 40.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$44.54B

 BTSG

BrightSpring Health Services, Inc.

$12.02B

 TEM

Tempus AI, Inc.

$11.66B

 HQY

HealthEquity, Inc.

$7.95B

 HNGE

Hinge Health, Inc.

$7.45B

 WAY

Waystar Holding Corp.

$4.81B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Omnicell, Inc.

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Visit website →